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Background: The target of rapamycin complex 1 (TORC1) is an evolutionarily conserved signal transduction
pathway activated by environmental nutrients that regulates gene transcription to control cell growth and
proliferation. How TORC1 modulates chromatin structure to control gene expression, however, is largely unknown.
Because TORC1 is a major transducer of environmental information, defining this process has critical implications for
both understanding environmental effects on epigenetic processes and the role of aberrant TORC1 signaling in
many diseases, including cancer, diabetes, and cardiovascular disease.
Results: To elucidate the role of TORC1 signaling in chromatin regulation, we screened a budding yeast histone H3
and H4 mutant library using the selective TORC1 inhibitor rapamycin to identify histone residues functionally
connected to TORC1. Intriguingly, we identified histone H3 lysine 37 (H3K37) as a residue that is essential during
periods of limited TORC1 activity. An H3K37A mutation resulted in cell death by necrosis when TORC1 signaling
was simultaneously impaired. The induction of necrosis was linked to alterations in high mobility group (HMG)
protein binding to chromatin. Furthermore, the necrotic phenotype could be recapitulated in wild-type cells by
deregulating the model HMG proteins, Hmo1 or Ixr1, thus implicating a direct role for HMG protein deregulation as
a stimulus for inducing necrosis.
Conclusions: This study identifies histone H3 and H4 residues functionally required for TORC1-dependent cell
growth and proliferation that are also candidate epigenetic pathways regulated by TORC1 signaling. It also
demonstrates a novel role for H3K37 and TORC1 in regulating the binding of select HMG proteins to chromatin and
that HMG protein deregulation can initiate a necrotic cell death response. Overall, the results from this study
suggest a possible model by which chromatin anchors HMG proteins during periods of limited TORC1 signaling,
such as that which occurs during conditions of nutrient stress, to suppress necrotic cell death.
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Environmental influences on eukaryotic cell growth, prolif-
eration, and development have well-documented effects on
epigenetic processes [1,2]. However, the mechanisms
underlying the regulation of epigenetic, or chromatin,
pathways by the environment remains largely unknown
[1,2]. Chromatin structure and function is modulated by
factors controlling the packaging of DNA with histone pro-
teins, including histone post-translational modifications,* Correspondence: rlaribee@uthsc.edu
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reproduction in any medium, provided the orDNA methylation, ATP-dependent chromatin-remodeling
enzymes, noncoding RNA, and the incorporation of his-
tone variants [3]. Although considerable progress defining
the biochemical pathways regulating chromatin has been
made, determining how these pathways are themselves
controlled by environmental stimuli remains a major chal-
lenge in the field of epigenetics.
The eukaryotic target of rapamycin (TOR) pathway is
an environmentally regulated signaling pathway acti-
vated by nutrients (predominantly amino acids), growth
factors, and energy states to promote anabolic processes
necessary for cell growth and proliferation while actively
suppressing such catabolic processes as autophagy [4,5].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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TOR complex 1 (TORC1) and TOR complex 2 (TORC2)
pathways [6,7], only TORC1 is directly regulated by nutri-
ent signals. TORC1 signaling regulates the transcriptional
and translational apparatuses that promote growth and
proliferation and this complex is inhibited by the
macrolide rapamycin. Genetic analyses in yeast have iden-
tified many TORC1 pathway members since mutations in
genes coding for these factors typically modify sensitivity
to rapamycin [5,8]. In yeast, TORC1 consists of either the
Tor1 or Tor2 kinases, Kog1 (a homolog to mammalian
Raptor), Lst8 and Tco89 subunits [5]. Intravacuolar amino
acid levels are registered by the EGO complex, which
consists of the Ego1 and Ego3 proteins along with the
Rag GTPases Gtr1 and Gtr2. EGO then recruits TORC1
to the vacuole membrane, resulting in TORC1 activation.
TORC1 then signals to downstream effectors to regulate
transcriptional and translational processes controlling cell
growth and proliferation [9]. The best-characterized
TORC1 target in yeast is the AGC kinase family member
Sch9, which is a functional ortholog to the Akt/PKB and
ribosomal S6 kinases [10]. Sch9 is phosphorylated on mul-
tiple serine and threonine residues by TORC1, resulting in
Sch9 activation [11]. Sch9 then phosphorylates a number
of downstream factors involved in diverse biological pro-
cesses, including regulators of ribosomal transcription,
mRNA export, and protein translation [12].
The Tor1 kinase can also be recruited to the promoter
regions of the RNA polymerase I and III (Pol I and Pol III)
transcribed 35S and 5S ribosomal DNA (rDNA) genes, re-
spectively, to activate their transcription [13,14]. This
process is also conserved in mammals, as mTor directly
regulates transcription by all three RNA polymerases
[15-17]. Transcriptional regulation requires significant al-
terations to chromatin structure and function but how
TORC1 regulates chromatin to mediate its transcriptional
effects has yet to be defined in detail. Previous studies
have linked TORC1 to both the RSC chromatin-
remodeling complex [18] and the Esa1 histone acetyl-
transferase [19]. In addition, TORC1 activation of Sch9
leads to phosphorylation of the transcriptional repressors
Stb3, Dot6, and Tod6 and the disruption of Rpd3-
dependent histone deacetylase repression of ribosomal
protein (RP) and ribosomal biogenesis (Ribi) genes [20].
TORC1 has also been functionally linked to Rpd3, inde-
pendently of these transcriptional repressors [21]. How-
ever, the full extent of TORC1 signaling to the epigenome,
and the underlying mechanisms involved, remains to be
determined.
We have pursued a chemical genomics approach to
probe how TORC1 interacts with chromatin as an initi-
ation point for identifying mechanisms by which the en-
vironment influences the epigenome. Utilizing a library
of histone H3 and H4 mutants [22], we have identified anumber of individual histone residues, many of which
are known to be post-translationally modified, that are
functionally linked to TORC1 signaling. We have char-
acterized in detail a subset of these mutants and identi-
fied an essential role for histone H3 lysine 37 (H3K37)
in anchoring select high mobility group (HMG) proteins
to chromatin during periods of limited TORC1 activity.
Disruption of this histone-HMG contact residue com-
bined with reduced TORC1 signaling resulted in cell
death by necrosis. Furthermore, necrosis was recapitu-
lated in an otherwise wild-type cell by the transient, in-
dividual overexpression of multiple HMG proteins,
suggesting a direct role for HMG protein deregulation in
inducing necrosis.
Results
Identification of histone H3 and H4 residues functionally
linked to TORC1
To identify histone H3 and H4 residues genetically
connected to TORC1 signaling, we screened a histone
H3/H4 mutant library using a sub-inhibitory (25 nM)
concentration of rapamycin to identify those mutants
exhibiting altered rapamycin sensitivity. Each mutant
was screened at least twice and the results were scored
as described in the Methods. For each mutant exhibiting
a reproducible rapamycin phenotype, we also analyzed
any other amino acid substitutions at that position that
were available in the library. For example, mutations at
lysine residues prompted us to analyze corresponding ly-
sine to arginine (which restores positive charge but pre-
vents acetylation) and lysine to glutamine (which mimics
constitutive acetylation) changes. The results for histone
H3 and histone H4 are summarized in Tables 1 and 2,
along with their positions in the nucleosome as anno-
tated in the HistoneHits database [23]. Intriguingly, 30
(≈26%) H3 and 13 (≈14%) H4 mutants demonstrated al-
tered rapamycin phenotypes, most of which were sensi-
tive (≈73% of all hits for histone H3 and ≈92% of all hits
for histone H4, see Tables 1 and 2). A much smaller per-
centage of resistant mutants (≈27% for histone H3 and
≈8% for histone H4) were identified. In general, more
robust rapamycin phenotypes, either sensitive or resist-
ant, were identified for histone H3 mutants relative to
histone H4, which is also consistent with the overall
screening results. These data suggest histone H3 may
have a greater functional role in TORC1 signaling rela-
tive to histone H4.
Histone H3K14A and H3K37A rapamycin sensitivity
exhibit functional differences
To explore in detail how these mutants affect TORC1-
dependent processes, we focused on a subset of histone
H3 mutants that resulted in either robust rapamycin re-
sistance (H3T3A, H3Q5A and H3S57A) or sensitivity
Table 1 Histone H3 mutants exhibiting altered rapamycin sensitivity
Histone H3 residue Rapamycin phenotype Nucleosome location Source
A1S −1 Tail This study
T3A +1 Tail This study
T3D 0 Tail This study
Q5A +2 Tail This study
Q5E +2 Tail This study
K14A −2 Tail [36]
K14R 0 Tail This study
K14Q 0 Tail This study
R17A −2 Tail This study
R17K −2 Tail This study
K18A −1 Tail [36]
K18R −2 Tail This study
K18Q 0 Tail This study
K23A −1 Tail [36]
K23R 0 Tail This study
K23Q 0 Tail This study
S28A −2 Tail This study
S28D 0 Tail This study
P30A −1 Tail This study
K37A Lethal Tail This study
K37R 0 Tail This study
K37Q 0 Tail This study
R49A −2 Lateral This study
R49K 0 Lateral This study
K56A −3 Lateral [36]
K56R −2 Lateral [36]
K56Q +2 Lateral [36]
S57A +1 Disk [36]
S57D +1 Disk [36]
E73A −1 Disk This study
E73Q −1 Disk This study
Q76A −1 Disk This study
Q76E −1 Disk This study
T80A +1 Disk This study
T80D −1 Disk This study
L82A −1 Disk This study
R83A −2 Lateral This study
R83K 0 Lateral This study
Q85A −2 Lateral This study
Q85E 0 Lateral This study
S86A −2 Lateral This study
S86D −2 Lateral This study
L92A +1 Buried This study
E105A −1 Disk This study
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Table 1 Histone H3 mutants exhibiting altered rapamycin sensitivity (Continued)
A110S −1 Buried This study
A111S −1 Buried This study
A114S −1 Disk This study
V117A −3 Lateral This study
Q120A +1 Lateral This study
K121A −1 Disk This study
K121R 0 Disk This study
K121Q −1 Disk This study
K122A −1 Disk This study
K122R −3 Disk This study
K122Q −1 Disk This study
R129A +1 Disk This study
R129K 0 Disk This study
Total number of H3 mutants screened 114
Number of H3 mutants with phenotype 30
Percentage of total H3 mutants with phenotype 26.3%
Percentage of H3 mutants with resistant phenotypes 26.7%
Percentage of H3 mutants with sensitive phenotypes 73.3%
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type (H3WT) strain. Intriguingly, H3K37A was the only
mutant that completely prevented growth on rapamycin
(Figure 1A and Table 1), suggesting an essential role for
this residue in TORC1 signaling. This rapamycin sensitivity
cannot be explained as a loss of H3K36 or H3P38 post-
translational modifications, as neither the H3K36A nor the
H3P38A mutation were identified in our screen as having
significant rapamycin phenotypes (data not shown). We
next determined whether these mutations also affected
sensitivity to caffeine which is another, albeit less specific,
inhibitor of TORC1 [24,25]. Surprisingly, only H3K37A
exhibited increased sensitivity to 12 mM caffeine while all
other mutants, including H3K14A, grew comparable to
the wild-type strain (Figure 1B). To determine whether the
H3K14A and H3K37A rapamycin sensitivity could be res-
cued by increased TORC1 signaling, we transformed the
wild-type strain and each mutant with a control vector or
a vector expressing a mutant Tor1 kinase (Tor1A1957V) that
has increased kinase activity in vitro [24]. Under these con-
ditions, wild-type cells expressing Tor1A1957V grew consid-
erably better in the presence of rapamycin than wild-type
cells carrying the control vector (Figure 1C). This trend
was mirrored by the H3K14A mutant, albeit the colony
sizes in the Tor1A1957V expressing H3K14A cells were still
smaller than wild-type colonies. Interestingly, while expres-
sion of Tor1A1957V in the H3K37A mutant did rescue
growth, this mutant still grew more poorly than the
H3K14A or H3WT (Figure 1C). These differences areunlikely to be caused by differential expression of the
TOR1A1957V plasmid as Tor1A1957V protein levels were
equivalent between the strains (Additional file 1). These re-
sults demonstrate that the rapamycin sensitivity identified
in H3K14A and H3K37A mutants is due specifically to de-
creased TORC1 activity.
In budding yeast, TORC1 phosphorylates the down-
stream Sch9 kinase to mediate some TORC1-regulated
functions. To determine whether the rapamycin-induced
growth defects in H3K14A and H3K37A mutants were
due to decreased Sch9 activation, we transformed wild-
type, H3K14A, and H3K37A yeast with control vector or
vector expressing the Sch92D3E mutant. This mutant has
acidic amino acid changes at five of the phosphoacceptor
sites normally phosphorylated by TORC1, resulting in a
Sch9 kinase that is active independently of upstream
TORC1 activity [11]. While cells carrying control vector
or the Sch92D3E expression vector grew normally on con-
trol plates, we observed markedly different results in the
presence of rapamycin. Wild-type cells carrying Sch92D3E
grew more poorly on rapamycin plates when Sch92D3E
was expressed compared with control vector (Figure 1D),
although the significance of this growth defect is currently
unknown. In the H3K14A mutants, the Sch92D3E plasmid
exhibited a partial reversal of their rapamycin sensitivity,
suggesting that the rapamycin-induced growth defects in
this mutant are due at least in part to decreased Sch9 ac-
tivity. Surprisingly, Sch92D3E did not rescue growth of
H3K37A on rapamycin (Figure 1D). This effect was not
Table 2 Histone H4 mutants exhibiting altered rapamycin sensitivity
Histone H4 residue Rapamycin phenotype Nucleosome location Source
L10A −1 Tail This study
G14A −1 Tail This study
K20A −1 Disk This study
K20R 0 Disk This study
K20Q −1 Disk This study
L22A −1 Disk This study
G28A −1 Disk This study
I29A −1 Buried This study
S47A −1 Lateral This study
S47D +1 Lateral This study
S64A −1 Disk This study
S64D −1 Disk This study
I66A −1 Buried This study
V81A +1 Buried This study
Y88A −1 Disk This study
Y88E 0 Disk This study
Y88F 0 Disk This study
G94A −1 Disk This study
Y98A −1 Buried This study
Y98E −1 Buried This study
Y98F 0 Buried This study
Total number of H4 mutants screened 94
Number of H4 mutants with phenotype 13
Percentage of total H4 mutants with phenotype 13.8%
Percentage of H4 mutants with resistant phenotypes 7.7%
Percentage of H4 mutants with sensitive phenotypes 92.3%
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mutant relative to wild-type, as Sch92D3E was expressed
comparably in the different strains (Additional file 1).
The Ras/PKA pathway is an essential regulator of cell
growth and proliferation that is activated predominantly
by glucose availability [26-28]. Ras/PKA and TORC1
also constitute the two main nutrient-regulated signaling
pathways in yeast. We next determined whether these his-
tone mutants exhibited sensitivity to reduced Ras/PKA ac-
tivity, since TORC1 and Ras/PKA signaling have been
both positively and negatively linked to each other [26-28].
A control vector or a multicopy vector expressing the high
affinity phosphodiesterase PDE2, which decreases cAMP
levels and reduces PKA signaling [29], was transformed
into H3WT and the individual histone mutants. Surpris-
ingly, all histone mutants except for H3S57A tolerated
lower PKA signaling comparably to wild-type strains
(Figure 1E). The H3S57A mutant exhibited mild sensitiv-
ity to reduced PKA activity, suggesting it may befunctionally important for the downstream effects of the
Ras/PKA pathway. Collectively, these results demonstrate
that H3K37A is absolutely essential for growth during
conditions of reduced TORC1, but not Ras/PKA, signaling
and that this requirement is independent of the activation
of the downstream TORC1 effector kinase Sch9.
TORC1-regulated gene expression is disrupted in a subset
of histone H3 mutants
We next asked whether these histone H3 mutants altered
TORC1-regulated gene transcription in a manner consist-
ent with their rapamycin phenotype. Since transcription of
the RP genes occurs as a regulon [30], for these experi-
ments we analyzed the expression of the RP gene RPS14B
as a model TORC1-regulated RNA polymerase II (Pol II)
transcriptional target. Surprisingly, in the absence of
rapamycin, the rapamycin-resistant mutants H3T3A and
H3Q5A reduced RPS14B expression whereas the other





















































Figure 1 Selective effects of histone H3 residues on TORC1-regulated cell growth. (A) Subset of histone H3 residues identified in chemical
genomics screen. Equal numbers of cells were 5-fold serially diluted and spotted to control (yeast extract/peptone/dextrose (YPD)) or YPD
containing 25 nM rapamycin plates. Plates were incubated at 30°C for 4 days before photographing. (B) As (A), except cells were spotted to
control YPD or YPD plates containing 12 mM caffeine. (C) A hyperactive Tor1 kinase (Tor1A1957V) rescues H3K14A and H3K37A growth on
rapamycin. The indicated strains were transformed with control vector or vector expressing Tor1A1957V and spotted to SC-leucine or SC-leucine
containing 25 nM rapamycin. Plates were incubated at 30°C for 4 days. (D) Sch9 signaling rescues the H3K14A, but not H3K37A, TORC1
phenotype. The indicated strains were transformed with control vector or vector expressing Sch92D3E, spotted to either SC-uracil or SC-uracil
containing 25 nM rapamycin, and incubated as in (D). (E) H3S57A mutants are sensitive to decreased protein kinase A (PKA) signaling. Cells
carrying control vector or a high copy PDE2 expression vector were spotted to SC-leucine plates and incubated at 30°C for 4 days. leu, leucine;
Rap, rapamycin; SC, synthetic complete medium; ura, uracil; WT, wild-type.
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ference in RPS14B expression in H3TA and H3Q5A mu-
tants relative to wild-type strains was erased (Figure 2A).
Intriguingly, while the H3K37A mutation did not affect
RPS14B expression in the absence of rapamycin, there
was a dramatic reduction in RPS14B expression after
rapamycin treatment (Figure 2A). Neither the H3K14A
nor the H3S57A mutants significantly affected RPS14B
expression under either condition (Figure 2A). The de-
creased RPS14B expression in both the H3T3A and
H3Q5A mutants is probably not caused by loss of adjacent
H3K4 methylation as a H3K4A mutant resulted in in-
creased RPS14B expression relative to H3WT (Figure 2B).We next monitored expression of the RNA Pol I tran-
scribed polycistronic 35S rRNA and the 5S rRNA, which
is transcribed by RNA Pol III. The 35S rRNA is co-
transcriptionally and post-transcriptionally processed into
the mature 18S, 5.8S, and 25S rRNAs, which have rela-
tively long half-lives [31]. Their expression can also be
maintained under conditions that significantly reduce the
number of rDNA repeats [32]. Since their steady-state
levels may not accurately reflect changes to Pol I tran-
scriptional activity, we also analyzed expression of the
ITS1 sequence that lies between the 18S and 5.8S rRNA
sequences [31]. ITS1 is transiently present in the nascent



















































































































Figure 2 Histone H3 mutants have differential impacts on TORC1-regulated gene expression. H3WT and the indicated histone mutants
were grown to log phase and then mock treated or treated with 25 nM rapamycin for 1.5 hours. Total RNA was extracted, cDNA synthesized
using random hexamer primers, and target gene expression analyzed by qPCR. The expression of all target genes was normalized to the ACT1
housekeeping gene. (A) Expression of the RNA Pol II transcribed ribosomal protein gene, RPS14B, in the indicated strains. (B) Expression of RPS14B
and the RNA Pol III transcribed 5S rRNA were analyzed in H3WT and H3K4A. (C) 5S rRNA expression in the indicated histone strains. (D)
Expression of the RNA Pol I transcribed ITS1-containing 35S rRNA. Individual histone H3 mutants are expressed relative to the H3 wild-type strain
(H3WT), which is set to a value of 1. Data are the average and standard deviation of four independent experiments with significance determined
by Student’s t test. *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.0005. Rap, rapamycin.
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and co-transcriptional 35S processing [35,36]. Expression
of the 5S rRNA in the absence of rapamycin was normal
for all mutants except H3Q5A, where 5S rRNA levels
were significantly reduced (Figure 2C). This reduction was
not due to loss of H3K4 methylation, as the H3K4A
mutation did not affect 5S expression (Figure 2B). After
rapamycin treatment, 5S rRNA levels were still reduced in
the H3Q5A mutant; however, under these conditions the
H3K37A mutant also exhibited a dramatic reduction in 5S
rRNA levels (Figure 2C). Interestingly, ITS1 expression
was modestly elevated in the H3K37A mutant approxi-
mately two-fold before rapamycin treatment (Figure 2D),
suggesting either a modest increase in Pol I transcription
or a decrease in co-transcriptional rRNA processing [36].
However, ITS1 levels decreased after rapamycin treatment
indicating a reduction in Pol I transcription. Quantifica-
tion of 18S and 25S rRNA levels revealed only marginal
changes in their expression (Additional file 2). These re-
sults implicate H3T3 and H3Q5 as having critical roles in
the regulation of TORC1-specific gene regulation medi-
ated by Pol II- and Pol III-dependent mechanisms and
that H3K37A is critical for TORC1-regulated gene expres-
sion when TORC1 activity is reduced.H3K37 has a critical role in TORC1-regulated cell-cycle
progression
TORC1 has a well-established role in regulating the G1/
S-phase of the cell cycle and a much more poorly under-
stood role in G2/M-phase regulation [5,37,38]. We next
determined whether these histone H3 mutants, and in
particular H3K37A, affected the cell cycle in a TORC1-
dependent manner. Asynchronous cultures of wild-type
yeast and the individual histone mutants were grown to
log phase, mock treated or treated with 25 nM rapamycin
for 1.5 hours and 4 hours before staining with SYTOX
Green and analysis by flow cytometry. No significant dif-
ferences in the cell-cycle profiles of wild-type cells and
histone mutants were detected in the mock-treated popu-
lations (Figure 3A, Additional file 3). However, a 1.5-hour
rapamycin treatment resulted in an enrichment of the
wild-type strain and mutants in G1 relative to S- and
G2/M phases but with significant heterogeneity in their
distribution. Wild-type, H3T3A, and H3K14A had similar
G1-phase distributions (approximately 63%, 59%, and 60%
respectively; see Additional file 3). However, the H3Q5A
and H3S57A mutations resulted in only approximately
50% of the cells in G1 (Figure 3A and Additional file 3).
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E
Figure 3 Histone H3K37A mutants exhibit a rapamycin-induced cell-cycle defect. (A) H3K37A mutants have defects in S-phase after
rapamycin treatment. H3WT and histone mutants were grown asynchronously to log phase before mock treating or treating with 25 nM
rapamycin for 1.5 hours and 4 hours. Cells were then stained with SYTOX Green and analyzed by flow cytometry. The percentages of cells in each
phase are presented and are listed in Additional file 3. (B) tco89Δ results in a complete absence of S-phase cells after rapamycin treatment. The
experiment in (A) was repeated using wild-type (BY4741) and tco89Δ. The percentages of cells in each phase are listed in Additional file 4. (C)
Both H3K37 charge and acetylation mutations rescue the cell-cycle phenotype. Experiment as (A), except H3WT, H3K37A, H3K37R, and H3K37Q
mutants were analyzed. Additional file 5 lists the percentages of each cell-cycle phase. (D) Strains from (C) were spotted to YPD control plates or
YPD plates containing 25 nM rapamycin and incubated at 30°C for four days. (E,F) H3K37A and tco89Δ mutants exhibit sensitivity to transient
rapamycin treatment. The indicated strains were grown to log phase before spotting equal numbers of cells to control YPD plates. The remaining
cultures were treated with 25 nM (sub-inhibitory) or 200 nM (inhibitory) rapamycin for 5.5 hours (E) or 24 hours (F). Cells were washed, 5-fold
serially diluted, spotted to YPD plates, and incubated at 30°C for 3 days. Rap, rapamycin; WT, wild-type.
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S-phase. Specifically, the wild-type strain H3T3A and
H3K14A mutants were distributed similarly (approximately
13%, 9%, and 11% respectively) while the H3Q5A and
H3S57A mutants had increased S-phase populations (ap-
proximately 20% and 23% respectively). These differences
were largely erased by 4 hours of rapamycin treatment,
however (Figure 3A, Additional file 3). While H3K37A
had a similar distribution of cells in G2/M relative to wild-
type at 1.5 and 4 hours post-rapamycin treatment, there
were significantly more cells in G1 (approximately 72%)
and far fewer cells in S-phase (3%) suggesting that
H3K37A was not transitioning from G1 into S-phase effi-
ciently (Figure 3A and Additional file 3).
We next asked whether a TORC1 mutant (tco89Δ)
that causes rapamycin hypersensitivity also affected cell-
cycle regulation comparable to the H3K37A mutation.
The experiment described in Figure 3A was re-
peated using wild-type and tco89Δ cells. While the pre-
rapamycin wild-type and tco89Δ populations were
similarly distributed throughout the cell cycle, the 1.5
and 4-hour post-rapamycin samples exhibited dramatic
differences (Figure 3B). The S-phase population in the
wild-type strain was reduced significantly at 1.5 hours
(approximately 3%) but increased to 14% by 4 hours
whereas the tco89Δ mutant had no detectable cells in
S-phase at either 1.5 or 4 hours (Figure 3B, Additional
file 4). These results suggested that both tco89Δ and
H3K37A might be functionally related in their effects on
cell-cycle regulation. We next repeated these cell-cycle
experiments using wild-type yeast and H3K37A,
H3K37R, and H3K37Q mutants to determine whether
restoring positive charge at this position (H3K37R) or
mimicking acetylation (H3K37Q) would restore a nor-
mal cell-cycle response. These experiments demonstrate
that both H3K37R and H3K37Q rescued the cell-cycle
defects (Figure 3C, Additional file 5) as well as growth
on rapamycin plates (Figure 3D). Although H3K37 can
be monomethylated or acetylated [39,40], it is unlikely
that loss of histone modifications at this position causes
the rapamycin phenotype, since both H3K37R and
H3K37Q rescue growth on rapamycin.
Disruption of the TORC1 activating complex, EGO, or a
tco89Δ results in an inability of cells to re-enter the cell
cycle and proliferate after transient rapamycin treatment
or nutrient starvation [9,41]. Owing to the similar effects
on cell-cycle regulation between H3K37A and tco89Δ
demonstrated above, we next compared the effects of tran-
sient rapamycin treatment on H3K37A relative to tco89Δ.
Initially, equal numbers of log phase H3WT, H3K37A,
wild-type, and tco89Δ cells were spotted to control YPD
plates. The remaining cultures were then treated with 25
nM (sub-inhibitory) or 200 nM (inhibitory) rapamycin for
5.5 hours before washing and spotting to YPD plates toexamine their ability to resume growth. After 5.5 hours,
the H3K37A mutant exhibited only minor growth defects
when treated with 25 nM rapamycin but had more
pronounced growth defects when treated with 200 nM
(Figure 3E). The tco89Δ mutant, however, was almost
completely growth-impaired after transient treatment with
25 nM rapamycin, while growth was completely prevented
by 200 nM rapamycin (Figure 3E). These experiments were
repeated with the rapamycin treatment time extended
to 24 hours. Under these conditions, H3K37A growth
was significantly impaired after 24 hours with 25 nM
rapamycin; this was further exacerbated by 200 nM
rapamycin treatment (Figure 3F). These results de-
monstrate that the H3K37A mutation negatively affects
cell-cycle progression and cell growth upon transient
rapamycin treatment in a manner dependent on both the
severity and length of time that TORC1 activity is im-
paired. These effects are similar, albeit not as severe, as
those detected in tco89Δ under identical conditions.
Limiting TORC1 activity in H3K37A results in necrosis and
is functionally linked to the disruption of high mobility
group (HMG) protein binding to chromatin
The inability of tco89Δ mutants to resume growth after
transient TORC1 inhibition has been attributed to a per-
manent exit from the cell cycle without a loss of viability
[9]. Given the similar phenotypes of tco89Δ and H3K37A,
we next tested whether H3K37A also maintained viability
after rapamycin treatment. Eukaryotic cell-death pathways
can be defined by staining cells with Annexin V (which in-
dicates apoptotic cells) and propidium iodide (PI) (which
indicates necrotic cells). To confirm that we could reliably
detect both forms of cell death, we subjected wild-type
cells to either a mock treatment or treatment with 80 mM
acetic acid for three hours, a condition known to induce
both apoptosis and necrosis [42]. While negligible Annexin
V and PI staining occurred in the mock-treated samples,
we readily detected both Annexin V and PI positive cells in
the acetic acid treated samples (Additional file 6), thus
demonstrating the reliability of this approach in analyzing
cell-death responses. We next repeated the 25 nM
rapamycin treatment of wild-type, tco89Δ, H3WT, and
H3K37A strains for 24 hours, stained the cells with
Annexin V and PI and analyzed them using flow cytome-
try. The wild-type, tco89Δ, and H3WT cells did not exhibit
significant staining with either Annexin V or PI before or
after rapamycin treatment (Figure 4A). These results con-
firm that while tco89Δ mutants are permanently growth
arrested after TORC1 inhibition they do maintain viability
[11]. However, the H3K37A mutant exhibited a significant
increase in PI positive, but not Annexin V positive, cells,
thus indicating that the cells were dying through a
nonapoptotic pathway (Figure 4A). Analysis of H3WT and




















































Figure 4 Limited TORC1 signaling in the H3K37A mutant selectively induces necrosis. (A) Wild-type (BY4741), tco89Δ, H3WT, and H3K37A
cells were grown to log phase before mock treating or treating with 25 nM rapamycin for 24 hours. Viability was determined by staining cells
with Annexin V and propidium iodide and analyzing by flow cytometry. (B) Mock-treated and rapamycin-treated H3WT and H3K37A mutants
from (A) were visualized by confocal microscopy. Scale bar represents 10 μm. (C) H3WT and H3K37A mutants were combined with an atg6Δ to
prevent autophagy and then spotted to control YPD or YPD + 25 nM rapamycin plates. Plates were incubated at 30°C for 4 days. (D) H3WT,
H3K37A, and the mitochondrial-deficient (ρ-) derivative strains from each background were spotted to control YPD, YP containing 3% glycerol
and YPD containing 25 nM rapamycin plates. The YPD and YP + 3% glycerol plates were incubated at 30°C for 3 days while the YPD + 25 nM
Rap plates were incubated at 30°C for 7 days. PI, propidium iodide; rap, rapamycin.
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swollen than the mock-treated H3K37A cells or H3WT
cells in either condition (Figure 4B).Both autophagy, which is normally suppressed by
TORC1, and mitochondrial dysfunction can be a source
of nonapoptotic cell death [43]. We reasoned that if
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gic mechanism, then preventing autophagy by deleting the
gene coding for the essential autophagy regulator, Atg6,
would rescue H3K37A rapamycin growth. To test this, we
engineered atg6Δ in both the H3WT and H3K37A back-
grounds and spotted cells to control and rapamycin plates.
Both the H3WT and H3WT atg6Δ grew comparably on
rapamycin plates yet neither H3K37A nor the H3K37A
atg6Δ grew (Figure 4C), demonstrating that the H3K37A
mutants were dying through a necrotic, but not autopha-
gic, cell-death pathway. Furthermore, induction of necro-
sis probably does not require functional mitochondria, as
mitochondrial-deficient H3K37A cells (ρ-) also failed to
rescue growth on rapamycin (Figure 4D). Therefore,
H3K37A mutants undergo a mitochondrial-independent
necrotic cell-death response under conditions of limited
TORC1 signaling.
H3K37 makes a direct contact with the mammalian high
mobility group box 1 (HMGB1) protein in in vitro binding
assays [44]. We speculated that rapamycin-induced necro-
sis in H3K37A may be functionally linked to decreased
chromatin association of yeast HMG proteins. Yeast have
seven HMG proteins, six of which (Nhp6a, Nhp6b, Abf2,
Ixr1, and Hmo1) share significant homology to HMGB1 as
determined by BLAST analysis of human HMGB1 against
the Saccharomyces genome database [45,46]. To determine
whether the H3K37A mutation impacts HMG chromatin
association, we genomically tagged two distinct model
HMG proteins, Nhp10 and Hmo1, with a 6XHA epitope
in the H3WT and H3K37A backgrounds. We chose to
examine Nhp10 because it is a component of a chromatin-
remodeling complex, INO80, that has broad roles in tran-
scription, DNA repair, and DNA replication [47,48]. As
such, altered binding of Nhp10 by TORC1-regulated chro-
matin changes has the potential to affect a variety of gen-
omic processes that could be functionally linked to the
H3K37A phenotype. Hmo1 was chosen because this HMG
protein regulates TORC1-dependent gene transcription
[49-51] and its chromatin binding is affected by TORC1-
regulated histone acetylation [36]. These strains were
grown to log phase and either mock treated or treated with
25 nM rapamycin for 30 minutes or 2 hours before pro-
cessing samples into soluble and chromatin-bound frac-
tions. These fractions were then analyzed by α-HA
immunoblots to detect the presence of Nhp10 or Hmo1.
Under these conditions, rapamycin treatment in H3WT
had no effect on Nhp10 chromatin association after 30 mi-
nutes but did modestly decrease Nhp10 binding after
two hours (Figure 5A). Intriguingly, TORC1 inhibition in
H3K37A resulted in decreased Nhp10 chromatin associ-
ation at both 30 minutes and 2 hours (Figure 5A). Identical
experiments in the Hmo1 background revealed a modest
decrease in Hmo1 chromatin association in the H3WT
background at 30 minutes while the H3K37A mutation didnot significantly reduce Hmo1 binding under these condi-
tions (Figure 5B). The difference in Hmo1 binding under
these conditions in the H3WT and H3K37A is not com-
pletely understood. However, one possible explanation
could be that the H3K37A mutation creates significant se-
lective pressure for cells to maintain Hmo1 bound to
TORC1 regulated genes during short periods of TORC1
inhibition and that prolonged TORC1 inhibition may ul-
timately result in decreased Hmo1 binding. Unfortunately,
Hmo1 protein levels decrease upon longer rapamycin
treatment (data not shown) so we were not able to ascer-
tain Hmo1 chromatin association reliably at these later
time points. Membranes were also probed for histone H3
and the cytoplasmic protein glyceraldehyde-6-phosphate
dehydrogenase (G6PDH) to control for the quality of the
soluble and chromatin fractions. The bulk of the cytoplas-
mic protein G6PDH was in the soluble fraction, while his-
tone H3 was detected almost exclusively in the chromatin
fraction (Figure 5A and B). We note that in these experi-
ments we consistently detected both a full-length histone
H3 band and a significant degradation product. Whether
this breakdown product is a consequence of the fraction-
ation protocol or is biologically relevant is unknown.
Because these chromatin association experiments meas-
ure global HMG binding and are more susceptible to
experimental variability, we chose next to perform chro-
matin immunoprecipitation at multiple ribosomal protein
genes to better quantify these effects on a gene-specific
basis. Relative to the no-tag control strain, Nhp10 binding
was significantly enriched at RPS14B, RPS5 and RPS13
(Figure 6A-C). Intriguingly, Nhp10 binding was reduced
in the H3K37A mutant even before TORC1 inhibition and
was not decreased further after a 30-minute rapamycin
treatment (Figure 6A-C). These results demonstrate that
the H3K37A mutation, even in the context of normal
TORC1 signaling, is capable of significantly impeding
Nhp10 binding at specific TORC1-regulated target genes.
While Hmo1 was enriched at RPS14B, its binding was not
significantly affected in either the wild-type strain or
H3K37A mutant before or after rapamycin treatment
(Figure 6A). Intriguingly, at RPS5, we detected a signifi-
cant increase in Hmo1 binding throughout the gene body
in the H3K37A rapamycin-treated samples (Figure 6B),
which is consistent with our chromatin association assays
(Figure 5B). We also examined binding of both Nhp10
and Hmo1 to RPS13, which was previously determined
not to be a Hmo1-regulated gene [49]. At RPS13, Nhp10
binding in the H3K37A mutant is similarly disrupted,
as seen for RPS14B and RPS5, whereas Hmo1 is not
significantly enriched relative to the negative control
(Figure 6C). Therefore, Nhp10 gene-specific binding is
disrupted in the H3K37A mutant even in the context of
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Figure 5 Reduced TORC1 signaling and the H3K37A mutation destabilizes Nhp10 binding to chromatin. (A) H3WT and H3K37A strains
expressing Nhp10-6XHA were grown to log phase before mock treating or treating with 25 nM rapamycin for 30 minutes (upper panels) or
2 hours (lower panels). Samples were fractionated into soluble and chromatin-bound proteins and 30 μg of each was immunoblotted with the
indicated antibody. Each set of immunoblots was exposed for the same length of time. Chromatin-bound Nhp10 and histone H3 were quantified
with ImageJ software and expressed as a ratio of Nhp10/histone H3. The rapamycin samples were normalized to the mock controls, which were
set to a value of 1. (B) As (A), except strains expressed Hmo1-6XHA. Only the 30-minute rapamycin treatment is shown, since Hmo1 protein levels
decrease significantly by 2 hours post-rapamycin treatment. Rap, rapamycin; WT, wild-type.
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inhibition has on Hmo1 and Nhp10, we performed indir-
ect immunofluorescence against these HA-tagged factors
using the rapamycin treatment conditions described previ-
ously. In the mock-treated samples, Hmo1 in both the
H3WT and H3K37A backgrounds exhibited a diffuse
staining, which became more condensed after 30-minute
rapamycin treatment (Figure 7A). This staining was spe-
cific for Hmo1 and Nhp10 (Figure 7B), as cells not ex-
pressing these HA-tagged factors exhibited no staining
(Additional file 7). Under these conditions, Hmo1 cellularlocalization does not appear to be significantly impacted
by the H3K37A mutation either before or after rapamycin
treatment (Figure 7A). However, since Hmo1 levels de-
crease upon longer rapamycin treatment, later time points
could not be reliably examined. As such, we cannot ex-
clude the possibility that Hmo1 localization at later time
points is affected by reduced TORC1 signaling.
Staining for Nhp10 demonstrated that, like Hmo1, it is
broadly distributed in both H3WT and H3K37A mutants
in the mock-treated samples. After 2-hour rapamycin
































































































































































































Figure 6 (See legend on next page.)
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(See figure on previous page.)
Figure 6 The H3K37A mutation selectively disrupts Nhp10, but not Hmo1, binding to ribosomal protein genes. The indicated strains
were either mock treated or treated with 25 nM rapamycin for 30 minutes before performing chromatin immunoprecipitation analysis for either
Nhp10 and Hmo1 binding at (A) RPS14B, (B) RPS5, (C) RPS13. The relative positions of primers used in qPCR are indicated below each graph. The
average and standard deviations of 3 (Nhp10) or 4 (Hmo1) independent experiments are plotted with significance determined by Student’s t test.
*P<0.05; **P<0.01; ***P<0.005. Rap, rapamycin.
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(Figure 7B). Interestingly, in the H3K37A mutant, Nhp10
distribution also becomes more condensed. However, in
some H3K37A cells, punctate foci of intense Nhp10 stain-
ing were also detected that did not completely localize to
the nucleus, suggesting that at least some Nhp10 might be
moving into the cytoplasm (Figure 7B, lower right merged
panel). This is specific for H3K37A, as rapamycin treat-
ment did not induce these Nhp10 foci in the H3WT back-
ground (Figure 7B, compare upper right and lower right
panels). The H3K37A rapamycin-treated cells were larger
than the matched H3WT cells; this finding is consistent
with the effect that longer-term (24-hour) rapamycin
treatment had on H3K37A (Figure 4B). Overall, these re-
sults demonstrate that TORC1 signaling is required for
steady-state global chromatin binding by Nhp10, and to a
minor extent, Hmo1, and that the H3K37A mutation
alone can negatively affect Nhp10 binding to specific
TORC1-regulated genes. These results also suggest that
decreased TORC1 signaling in H3K37A affects the cellular
distribution of Nhp10, resulting in at least some Nhp10
relocating to the cytoplasm.
Deregulation of HMG proteins actively induces necrosis
Relocation of HMGB1 and HMGB1 orthologs from the
nucleus to the cytoplasm has been used as an indicator
of necrosis in eukaryotes [52,53]. Our data implicate
TORC1 signaling as a candidate regulator of chromatin
binding for at least Nhp10 and perhaps other untested
HMG proteins as well. We considered the possibility
that decreased TORC1 activity might act in combination
with H3K37A to affect the chromatin association of one
or more HMG proteins and that this might actually con-
stitute an initiating signal for necrosis. To begin testing
this possibility, we transformed H3WT with either a
control vector or individual vectors expressing five
(HMO1, NHP6A, NHP10, ABF2 or IXR1) of the seven
yeast HMG proteins from the galactose-inducible GAL1
promoter [54]. We reasoned that high-level expression
of individual HMGs from the GAL1 promoter would
generate at least some non-chromatin-bound HMG pro-
tein. If non-chromatin-bound HMGs can initiate necro-
sis, then we would expect significantly impaired growth
responses when these factors are overexpressed.
Transformed cells were spotted to selective media
containing glucose (to repress) or galactose (to induce)expression of the indicated HMG factors and incubated
for three days. While all cell populations grew compar-
ably on glucose media, only cells carrying the control
vector grew well on galactose media. Expression of the
HMG genes HMO1, NHP6A, ABF2, or IXR1 resulted in
no growth and expression of NHP10 resulted in very
poor growth (Figure 8A). We selected Hmo1, Ixr1, and
Nhp10 for further analysis, since Hmo1- and Ixr1-
overexpressing cells failed to grow whereas Nhp10-
overexpressing cells grew, albeit poorly. We next deter-
mined whether transient galactose induction followed by
glucose repression would significantly impair cell
growth. Wild-type cells carrying control vector or either
GAL1-HMO1, GAL1-NHP10, or GAL1-IXR1 were grown
to log phase in selective media containing raffinose and
equal numbers of cells were spotted to control media
(pre-gal samples). The remaining cultures were treated
with 2% galactose for 5.5 or 24 hours and then washed
and spotted to glucose media and allowed to recover for
three days. Under these conditions, transient induction
of HMO1 for 5.5 hours significantly impaired growth, an
effect that was dramatically exacerbated after 24 hours
induction (Figure 8B). Although constitutive NHP10 ex-
pression resulted in poor growth, transient NHP10
expression did not impair growth after either 5.5 or
24 hours (Figure 8C). Transient induction of IXR1 for
5.5 hours did not significantly impair growth but after
24 hours IXR1 expression resulted in modest growth de-
fects (Figure 8D). Robust expression of Hmo1, Ixr1, and
Nhp10 protein was detected after a one-hour galactose
induction (Figure 8F), thus making these effects unlikely
to be due to significant differences in expression of these
HMGs from the GAL1 promoter.
To determine whether the growth defects in the
Hmo1- and Ixr1-overexpressing cells were due to loss of
cell viability, H3WT cells carrying either control, GAL1-
HMO1, GAL1-NHP10, or GAL1-IXR1 expression vectors
were induced with galactose for 24 hours. Cells were
then stained with Annexin V and PI and analyzed by
confocal microscopy. Neither the control vector nor the
GAL1-NHP10 vector resulted in significant Annexin V
or PI staining under these conditions (Figure 8E); this
result is consistent with the lack of significant growth
defects detected in cells transiently overexpressing
Nhp10 (Figure 8C). Both Hmo1 and Ixr1 overexpression



























Figure 7 The effect of TORC1 inhibition on Hmo1 and Nhp10
localization in H3WT and H3K37A. (A) H3WT and H3K37A strains
expressing Hmo1-6XHA were mock treated or treated with 25 nM
rapamycin for 30 minutes before staining with rhodamine-
conjugated α-HA antibody and DAPI. (B) As (A) except Nhp10-6XHA
expressing cells were treated with 25 nM rapamycin for two hours.
Cells were analyzed by confocal microscopy as described in the
Methods and the data are representative of four independent
experiments. Scale bar indicates 5 μm. Rap, rapamycin.
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sponse than Ixr1 (Figure 8E). These results are consist-
ent with the overall effects their transient expression hadon cell growth (compare Figure 8B and 8D). Intriguingly,
while significant necrosis was detected in both Hmo1-
and Ixr1-expressing cells, no increase in apoptotic cells
was observed. These results indicate that the growth de-
fects detected in Hmo1- or Ixr1-overexpressing cells are
due to loss of viability caused by necrosis whereas the
poor growth phenotype detected in Nhp10-expressing
cells (Figure 8A) is independent of cell death. Although
both Hmo1 and Ixr1 overexpression induced necrosis,
neither HMG alone caused the same enlarged, swollen
cell phenotype evident in the H3K37A rapamycin cells
(compare Figure 4B and Figure 8E). Therefore, the
H3K37A mutation probably affects chromatin binding
by multiple HMG proteins during conditions of reduced
TORC1 activity to cause these more severe morpho-
logical effects. Overall, these results implicate a role for
TORC1 signaling in promoting the chromatin binding of
HMG proteins and provide evidence that HMG deregu-
lation can actively initiate a necrotic cell-death response.
Discussion
Environmental nutrients affect chromatin regulation to
alter epigenetic processes controlling growth, proliferation
and developmental potential of eukaryotic cells [1,2]. The
mechanisms underlying this process remain poorly char-
acterized, yet it is essential that they are addressed, as they
have profound implications for many diseases, including
cancer, diabetes, and cardiovascular disease [1,2]. We have
begun to address this issue by utilizing the TORC1 path-
way as a model, since it is a critical transducer of nutrient
information in eukaryotes and is deregulated in numerous
diseases [55]. The rationale for our approach was predi-
cated on the idea that histone residues functionally linked
to TORC1, and as an extension those chromatin pathways
involving these residues, would exhibit altered growth re-
sponses upon rapamycin treatment. Our genetic screens
have identified a number of histone residues, predomin-
antly on histone H3, linked to TORC1 via this approach.
Many of these residues are known sites of histone post-
translational modification or are contact residues for non-
histone chromatin components, so we believe these data
will serve as an initiation point for delineating how
TORC1 regulates chromatin structure and function. Since
most of these histone residues are conserved from yeast to
man, our results suggest the possibility that TORC1 may
utilize a core group of evolutionarily conserved chromatin
pathways that includes a predominant role for histone H3.
In this study, we examined a subset of histone H3 mu-
tants exhibiting both sensitive (H3K14A and H3K37A)
and resistant (H3T3A, H3Q5A, and H3S57A) rapamycin
phenotypes to understand their specific functions in
the TORC1 pathway. Intriguingly, while H3K14A and
H3K37A were both sensitive to rapamycin, only H3K37A
exhibited sensitivity to the less specific TORC1 inhibitor
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for H3K37 under conditions of even mild TORC1
perturbation. Because Sch9 activation could rescue the
H3K14A but not the H3K37A rapamycin phenotype, these
experiments demonstrate that the role of H3K37 in the
TORC1 pathway is independent of the downstream
TORC1 effector kinase Sch9. Our data further suggest
that the essential nature of H3K37 is highly specific
for TORC1, since H3K37A was not affected by reduced
Ras/PKA signaling.
Except for H3K37A, neither the gene expression ana-
lyses nor the cell-cycle studies of the remaining histone
mutants resulted in clear outcomes corresponding to their
rapamycin phenotypes. These results suggest that their
contributions to the TORC1 phenotype are likely to be
complex in nature and cannot be ascribed simply to al-
tered ribosomal transcription or dysfunctional cell-cycle
dynamics. Interestingly, these studies did reveal previously
unappreciated roles for H3T3 and H3Q5 in TORC1-
regulated gene expression. Specifically, these residues were
demonstrated to be critical for RPS14B expression in
nutrient-replete conditions. The decreased RPS14B ex-
pression in H3T3A and H3Q5A were unlikely to be due
to loss of H3K4 methylation, as has been proposed [56],
since H3K4A increased RPS14B expression. Recently, a
study demonstrated that H3K4me3, which normally
demarcates actively transcribed genes, can behave as a
repressive chromatin modification specifically for RP gene
transcription under conditions of stress including that in-
duced by rapamycin treatment [57]. Therefore, our results
suggest that H3T3A and H3Q5A may actually impact
TORC1-regulated RP gene transcription by either dis-
rupting H3K4me3 demethylation or through mechanisms
independent of H3K4 post-translational modification
altogether. Furthermore, H3Q5 has a positive role in 5S
rRNA expression independent of H3T3 and H3K4me3
and thus may contribute uniquely to RNA Pol III-
dependent transcription.
Under nutrient-replete conditions, the minor increase in
ITS1-containing rRNA levels in H3K37A is likely to be
due to a disruption in rDNA chromatin structure required
for 35S rRNA co-transcriptional processing. This effect
could be similar in nature to that originally characterized
by our laboratory for mutants of the H3K56ac pathway
[36]. However, the remainder of the rapamycin-induced
gene expression and cell-cycle effects in H3K37A are
probably indirectly caused by the induction of cell death
upon TORC1 inhibition. This cell-death response in
H3K37A is clearly distinct from the severe growth defect
occurring in tco89Δ after TORC1 inhibition, since this
mutant maintains viability but is unable to re-enter the
cell cycle upon rapamycin removal. The lack of significant
Annexin V staining and the inability of the atg6Δ to rescue
H3K37A growth on rapamycin implicate necrosis as thecause of rapamycin-induced cell death in H3K37A. While
H3K37 can be monomethylated or acetylated [39,40], loss
of either of these modifications does not explain the cell-
death response, since both H3K37R and H3K37Q muta-
tions rescue growth on rapamycin. Instead, we believe the
H3K37A mutation probably disrupts an HMG contact
residue [44], which alters the chromatin association of a
subset of HMG proteins. This effect would then be further
exacerbated by changes to chromatin that occur on
TORC1 inhibition. These changes might include de-
creased H3K56ac, since TORC1 regulates this histone
modification and disruption of this chromatin pathway re-
sults in similar cell-death phenotypes [36,58]. Alterna-
tively, other histone post-translational modifications,
particularly those occurring on the histone H3 and H4
residues identified in this study, could be perturbed under
these conditions. These chromatin changes could act in
concert with the H3K37A mutation to impede HMG
chromatin binding further. Consistent with this concept,
we provide evidence that Nhp10 chromatin binding is im-
paired by both decreased TORC1 activity and the
H3K37A mutation. Since Nhp10 and select other HMG
proteins are constituents of ATP-dependent chromatin-
remodeling and histone chaperone complexes [47,59],
regulating their chromatin association by TORC1 signal-
ing could allow cells to adjust their transcriptional pro-
grams quickly in response to a rapidly changing nutrient
environment.
Our data demonstrate a significant role for TORC1 and
H3K37 in regulating chromatin binding by Nhp10. How-
ever, Nhp10 overexpression was insufficient to induce ne-
crosis, whereas both Hmo1 and Ixr1 overexpression could
induce robust necrosis. Intriguingly, neither Hmo1 nor
Ixr1 overexpression fully recapitulated the effects that
TORC1 inhibition had in the H3K37A background. In
total, our data suggest a speculative model by which severe
nutrient deprivation significantly reduces TORC1 activity
in wild-type cells, resulting in decreased chromatin bind-
ing by multiple HMG proteins simultaneously. In the
H3K37A background, the chromatin binding of a subset
of HMG proteins is already reduced, thus making this mu-
tant even more sensitive to minor perturbations in
TORC1 activity (Figure 8G). HMG chromatin dissociation
could then alter global gene transcription or lead to in-
creased localization of HMGs to the cytoplasm where they
would disrupt signaling pathways or organelles (perhaps
vacuoles/lysosomes) essential for maintaining cell homeo-
stasis [60-63]. Which HMG, or combination of HMGs,
evicted from chromatin is necessary to induce necrosis
and the mechanisms underlying this process will need to
be addressed in future studies. Intriguingly, if correct, this
model would directly implicate decreased HMG chroma-
tin binding as a cause of necrosis instead of a consequence
of necrotic cell death, as previously described [52,64]. This
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Figure 8 (See legend on next page.)
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Figure 8 Deregulation of HMG proteins induces necrosis. (A) H3WT cells were transformed with control vector or a vector expressing one of
the five indicated yeast HMG genes from the GAL1 promoter. Equal numbers of cells were 5-fold serially diluted and spotted to SC-uracil plates
containing glucose (repressive) or SC-uracil galactose (activating) media and incubated at 30°C for 4 days. (B-D) Cells containing control vector
and either the galactose-inducible Hmo1 (B), Nhp10 (C) or Ixr1 (D) expression vectors were grown to log phase in raffinose media before serially
diluting 5-fold and spotting to SC-uracil glucose plates. The remaining cultures were treated with 2% galactose for the indicated times before
washing and spotting as described. Plates were incubated for 3 days at 30°C. (E) H3WT cells carrying control, GAL1-HMO1, GAL1-NHP10, or
GAL1-IXR1 expression vectors were grown to log phase in SC-uracil raffinose media, induced with 2% galactose for 24 hours, stained with Annexin
V and PI, and then analyzed by confocal microscopy. Scale bar indicates 10 μm. (F) The strains from (B-D) were induced with 2% galactose for
1 hour before preparing whole-cell extracts. 30 μg of extract was resolved by SDS-PAGE and immunoblotted with α-HA antibody to detect the
HA-tagged Hmo1, Nhp10 and Ixr1. (G) Model for TORC1 signaling and regulation of HMG chromatin association. Details in the text.
Gal, galactose; PI, propidium iodide; ura, uracil, vect, vector.
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tiple models demonstrating that necrosis is an ancient,
genetically programmed cell-death pathway distinct from
apoptosis and sensitive to specific stress events [43]. Over-
all, this study provides a foundation for determining how
environmental nutrient signaling through TORC1 affects
epigenetic processes. It also suggests a previously unappre-
ciated role for chromatin as an HMG binding platform
that suppresses necrosis during periods of limited TORC1
signaling.
Conclusions
These studies provide the foundations for delineating how
environmental nutrients signal through the TORC1 com-
plex to mediate effects on the epigenome. Specifically, the
individual histone H3 and H4 residues functionally
interacting with the TORC1 pathway have been identified.
Since a number of these residues are sites of post-
translational modification, these residues could be the
endpoint of chromatin pathways regulated by TORC1 to
affect gene transcription and chromosome structure ne-
cessary for cell growth and proliferation. Excitingly, these
results also reveal an absolutely essential and unappreci-
ated role for histone H3K37 in suppressing necrosis dur-
ing periods of limited TORC1 activity that is linked to its
role in promoting HMG protein binding to chromatin.
Our results also provide direct evidence that HMG pro-
tein deregulation can be a stimulus for inducing necrosis,
unlike previous studies that correlated the release of
HMG proteins from chromatin as a consequence of ne-
crosis. Overall, these studies provide novel new insights
into TORC1 interactions with the epigenome and suggest
that one function of the chromatin fiber is to bind HMG
proteins under conditions of decreased TORC1 signaling
to prevent cell death by necrosis.
Methods
Yeast media, plasmids, cell growth conditions, and chemicals
All of the yeast histone mutants used in this study are
from the histone H3/H4 library derived by Dai et al.
[22] and purchased from Open Biosystems. Specificstrains and plasmids used throughout the study are listed
in Additional file 8. Strains YNL372 (H3WT), YNL401
(H3T3A), YNL357 (H3Q5A), YNL352 (H3K14A),
YNL403 (H3K37A), and YNL374 (H3S57A) used in our
detailed analyses are derivative strains from the histone li-
brary that were made Ura- by growth on 5-FOA media to
select for those clones that recombined out the URA3
marker. Unless otherwise stated, cells were grown in
nutrient-rich YPD (2% peptone, 1% yeast extract, 2% dex-
trose) or YPD containing 25 nM rapamycin. For growth
on selective synthetic complete medium (SC), SC contai-
ning 1 g/l of glutamic acid as a nitrogen donor and lacking
the appropriate dropout component was utilized. To gen-
erate ρ- mutants, H3WT and H3K37A strains were cul-
tured through two successive rounds of growth in SC
medium containing 25 μg/ml ethidium bromide. Single
colonies were then picked and the mitochondrial defi-
ciency phenotype was confirmed by lack of growth on a
nonfermentable carbon source (YP + 3% glycerol). All
yeast growth media and reagents were purchased from
Research Products International or US Biologicals. All
chemicals used in these experiments were purchased from
Fisher Scientific or Sigma-Aldrich.
The rapamycin screens of the histone library were
performed by growing wild-type yeast and the indicated
mutants overnight in YPD at 30°C with shaking. The fol-
lowing day, equal cell numbers were 5-fold serially diluted
and replica spotted to control YPD or YPD containing
25 nM rapamycin plates and incubated at 30°C. Growth
was analyzed every day and photographs were typically
taken between three and six days. The results were scored
using the methodology described in Rizzardi et al. [65].
Briefly, those mutants exhibiting synthetic growth pheno-
types relative to wild-type controls were scored numerically
from 1 to 3, with 1 being approximately a 5-fold difference
in growth and 3 being a 125-fold difference in growth. Mu-
tants exhibiting growth defects were given negative values
while mutants showing enhanced growth were given posi-
tive values. A value of 0 indicates no difference from the
wild-type control strain. For the transient rapamycin treat-
ment and recovery experiments, cells were initially grown
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5-fold serially diluted and then spotted to YPD plates. The
remainder of each culture was treated with the specific
concentration of rapamycin for the indicated time and then
equal numbers of cells were gently pelleted, washed with
sterile water, diluted, and spotted, as described. Pictures
were taken after 3 days incubation at 30°C.
RNA extraction, cDNA synthesis, and quantitative PCR
(qPCR)
RNA was extracted using Tri-Reagent (Sigma-Aldrich)
and bead beating with subsequent extensive digestion
using DNase I to eliminate contaminating genomic DNA.
1 μg total RNA was then used in a cDNA synthesis reac-
tion with random primers and the Im-Prom II cDNA syn-
thesis kit (Promega, Inc.). cDNAs were resuspended to a
final volume of 100 μl, diluted 1:5 and then used in qPCR
with primers to the indicated genes. The gene-specific sig-
nals were normalized to the internal control gene ACT1
using the formula 2(ACT1 Ct-Target Gene Ct). After
normalization, the wild-type sample was set to a value of 1
and each mutant expressed relative to wild-type with stat-
istical significance determined by Student’s t test. Primer
sequences are available upon request.
Whole-cell extract preparation, immunoblotting, and
antibodies
Whole-cell extracts from log phase yeast cultures were
prepared in protein extraction buffer (10 mM Tris,
pH 8.0, 150 mM NaCl, 0.1% Nonidet P-40, 10% glycerol,
1 mM DTT) containing protease and phosphatase inhibi-
tors by bead beating, as described previously [36]. For im-
munoblot analyses, 30 μg of whole-cell extracts were
resolved by 10% SDS-PAGE and then transferred to
polyvinylidene difluoride membrane before incubating
with the indicated antibody. The α-HA antibody was pur-
chased from Santa Cruz Biotechnology, Inc., the α-β actin
antibody was purchased from Abcam, the α-G6PDH anti-
body was obtained from Sigma-Aldrich, and the α-H3
antibody was purchased from Active Motif. After incuba-
tion with the appropriate secondary antibody, chemi-
luminescence was performed using the Immobilon
Chemiluminescent HRP system from Millipore and sam-
ples were detected by exposure to film.
Chromatin association assay
The chromatin association assay is a combination of two
previously published protocols [66,67]. Briefly, 100 ml of
cells (OD600 ≈ 0.5) were collected and washed with protein
solubilization buffer (PSB) (20 mM Tris-Cl pH 7.4, 2 mM
EDTA, 100 mM NaCl, 10 mM β-mercaptoethanol) and
then solubilization buffer (SB) (1 M sorbitol, 20mM Tris-
Cl pH 7.4). Cell pellets were then incubated with 1 mg/ml
Zymolyase 20T in SB buffer for 30 minutes to 1 hour atroom temperature. The resulting spheroplasts were
washed twice with 1 ml LB buffer (0.4 M sorbitol, 150
mM potassium acetate, 2 mM magnesium acetate, 20 mM
PIPES, with the pH adjusted to 6.8 using potassium
hydroxide) containing protease inhibitors (1 mM phenyl-
methanesulfonylfluoride, 10 μg/ml leupeptin, 10 μg/ml
aprotinin, 10 μg/ml pepstatin) and then pelleted at
2000 rpm for 5 minutes at 4°C. Cell pellets were
resuspended in 250 μl LB buffer plus 1% Triton X-100
containing protease inhibitors and incubated on ice with
occasional mixing for 10 minutes. 125 μl of this sample
was removed to use as the total fraction while the remain-
der of the lysate was centrifuged at 5000g for 15 minutes
at 4°C. The supernatant (soluble protein fraction) was re-
moved while the chromatin pellet was washed in 125 μl
LB containing 1% Triton X-100 and protease inhibitors
and then pelleted at 5,000g for 15 minutes at 4°C. The
supernatant was discarded and the resulting chromatin
fraction was resuspended in 125 μl LB buffer containing
1% Triton X-100 and protease inhibitors. The Bradford
assay was used to normalize protein levels for the total,
soluble, and chromatin-bound fractions and 30 μg of each
was used for SDS-PAGE and immunoblot analysis. The
levels of chromatin-bound HMG and histone H3 proteins
were quantified by ImageJ analysis, expressed as a ratio of
HMG/histone H3 and the rapamycin-treated sample then
normalized to the mock-treated sample, which was set to
a value of 1.
Chromatin immunoprecipitation analysis
A no-tag control and the indicated H3 wild-type or
H3K37A mutants carrying either Nhp10-6xHA or Hmo1-
6XHA were grown in YPD to an OD600 = 1.0 to 1.5 before
cross-linking for 15 minutes with 1% formaldehyde and
then quenching with 125 mM glycine for 5 minutes. Chro-
matin extracts were prepared and immunoprecipitation
was performed as described [36] using 500 μg of the chro-
matin extract and 1 μg of α-HA antibody. The
immunoprecipitated chromatin, as well as 10% of input
chromatin, was purified and eluted in 50 μl (for immuno-
precipitation) or 100 μl (for inputs). Samples were then di-
luted 1:5 for immunoprecipitation and 1:100 for inputs
before analyzing by real-time PCR. The enrichment was
determined using the following formula: 2(Input Ct-IP Ct).
The sample of H3 wild-type without rapamycin treatment
was set to a value of 1 and the remaining samples, includ-
ing the no-tag control, was expressed relative to this sam-
ple. Primer sequences are available upon request.
Flow cytometry and immunofluorescence analysis
The fluorescent dye SYTOX Green (Invitrogen, Inc.) was
used to stain yeast DNA as previously described [68]. Sam-
ples were analyzed on a BD LSD II flow cytometer using
Modfit software for data analysis at the UT flow cytometer
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follows. FITC-coupled Annexin V (ClonTech Laboratories,
Inc.) and PI (MP Biomedical, LLC) were used to stain live
cells, as previously described [69]. Briefly, yeast cells were
stained in binding buffer (10 mM HEPES/NaOH, PH 7.4,
140 mM NaCl, 2.5 mM CaCl2) with Annexin V at a con-
centration of 1μg/ml and a PI concentration of 25 μg/ml
for 20 to 30 minutes at room temperature. Slides were pre-
pared by pouring an agarose cushion to prevent movement
of the yeast cells and then analyzed using a 63X oil Olym-
pus objective on a Zeiss LSM 700 confocal microscope
with its own software to capture and analyze the images.
For the indirect immunofluorescence analysis of Hmo1
and Nhp10, cells were grown to log phase and then fixed
with 70% ethanol for one hour. Cells were then washed
three times with 5% BSA before staining with primary
mouse α-HA antibody (Santa Cruz Biotechnology, sc-
7392) at a 1:25 dilution (from a 1 mg/ml stock) overnight.
Cells were then washed three times with 5% BSA and
stained with secondary IgG goat anti-mouse antibody con-
jugated to rhodamine (Millipore, LOT: 219844) in a 1:25
dilution overnight. After washing three times with 5%
BSA, cells were subsequently stained with 2 ug/ml DAPI
(MP Biomedicals Lot No: M5816) for 30 minutes, washing
steps were repeated and the samples were then analyzed
by confocal microscopy.Additional files
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